key: cord-0970968-45pbvjpv
authors: Bin-Gouth, Abdulla Salem; Al-Shoteri, Sheikh; Mahmoud, Nuha; Musani, Altaf; Baoom, Nasser Ahmed; Al-Waleedi, Ali Ahmed; Buliva, Evans; Aly, Eman AbdelKareem; Naiene, Jeremias Domingos; Crestani, Rosa; Senga, Mikiko; Barakat, Amal; Al-Ariqi, Lubna; AL-Sakkaf, Khaled Zein; Shaef, Abeer; Thabet, Najeeb; Murshed, Ahmed; Omara, Samuel
title: SARS-CoV-2 Seroprevalence in Aden, Yemen: A population-based study
date: 2021-12-17
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.330
sha: 2678c48cdd22c1c7850d5444e0248e78a1ca18dc
doc_id: 970968
cord_uid: 45pbvjpv

Background In Yemen; initial surveillance of COVID-19 focused primarily on patients with symptoms or severe disease and The full spectrum of the disease are not clear. To the best of our knowledge, this is the first seroprevalence study done in Yemen. Methods It is a one-time cross-sectional investigation among 2000 participants from all age groups from four districts in Aden at southern Yemen. A multi-stage sampling method used. Data collected by using a well-structured questionnaire and blood sample were collected. Healgen COVID-19 IgG/IgM Rapid diagnostic Test (RDT) Cassette was used in all participants. All positive RDTs and 14% of the negative RDTs underwent ELISA test (WANTAI SARS-CoV-2 Ab Elisa Kit) Results A 549 out of 2001 participants were RDT positive and proved by ELISA giving the prevalence of COVID-19 infection to 27•4% and specifically the prevalence of IgG was 25%. The prevalence of asymptomatic COVID-19 infection in all the study group was 7•9%. The highest prevalence was observed in Al-Mansurah district (33•4%). Regarding socio-demographic factors females, housewives and history of contact a COVID-19 patients have significant higher prevalence rates (32%, 31% and 39% respectively). Conclusion high prevalence of SARS-CoV-2 antibodies was reported. Household contacts are the main factors for transmission.

-High prevalence of SARS-CoV-2 antibodies are detected in Aden population (27.4%). -Females are more exposed to infection than males -Household contacts are the most social groups exposed to infection -low prevalence of asymptomatic COVID-19 infection among the study participants (7·8%).

Summary Background: In Yemen; initial surveillance of COVID-19 focused primarily on patients with symptoms or severe disease and The full spectrum of the disease are not clear.

To the best of our knowledge, this is the first seroprevalence study done in Yemen.

Methods: It is a one-time cross-sectional investigation among 2000 participants from all age groups from four districts in Aden at southern Yemen. A multi-stage sampling method used. Data collected by using a well-structured questionnaire and blood sample were collected. Healgen COVID-19 IgG/IgM Rapid diagnostic Test (RDT)

Cassette was used in all participants. All positive RDTs and 14% of the negative RDTs underwent ELISA test (WANTAI SARS-CoV-2 Ab Elisa Kit)

Results: A 549 out of 2001 participants were RDT positive and proved by ELISA giving the prevalence of COVID-19 infection to 27·4% and specifically the prevalence of IgG was 25%. The prevalence of asymptomatic COVID-19 infection in all the study group was 7·9%. The highest prevalence was observed in Al-Mansurah district (33·4%).

Regarding socio-demographic factors females, housewives and history of contact a COVID-19 patients have significant higher prevalence rates (32%, 31% and 39% respectively).

Conclusion: high prevalence of SARS-CoV-2 antibodies was reported. Household contacts are the main factors for transmission.

Key Words: Antibodies, COVID-19 serosurvey, ELISA, Immunity, SARS-CoV-2 seroepidmiology.

COVID-19 pandemic spread quickly over the world since the first case was reported from Wahan, China in December 2019. In Yemen like all the limited resource countries (for example African countries) (Nkengasong JN & Mankoula W, 2020) where weak health-care systems, including inadequate surveillance and laboratory capacity, scarcity of public health human resources, and limited financial means as well as neither treatment nor vaccines, and without pre-existing immunity, these challenges make epidemiology of COVID 19 in Yemen is uncertain. It was reported elsewhere that uncertainty and underestimation of true cases may due to insufficient testing (Gupta M, 2020) .

To date initial surveillance has focused primarily on patients with symptoms or severe disease. The full spectrum of the disease, including the extent and fraction of mild or asymptomatic infections that do not require medical attention are not clear (WHO a. 2020) .

Because a great majority of Yemen's cases have been reported from hospital-based surveillance; estimates of the case fatality ratio, and other epidemiological parameters, will likely be lower than current estimates. Once the full spectrum of disease is able to be included in the denominator like asymptomatic or subclinical infected individuals, it will provide clear estimation of the problem. It was reported in different literatures that measuring fatality rates and projecting the number of deaths depend on estimates of the total number of infections (Spychalski P et al, 2020 . Onder G et al, 2020 . Li Lo et al, 2020 & Wu JT, 2020 but in the absence of seroprevalence survey it was estimated by multiplying number of cases with certain factor. However, the magnitude of that factor is highly uncertain.

Up to November 22nd 2020 (one week before this survey conducted), Yemen reported officially 2073 confirmed COVID-19 cases and 605 related deaths (CFR 29%) (WHO b 2020) and presumed community transmission occurred in large cities like Aden especially in May 2020. To date no sero-prevalence study done in Yemen to inform epidemic parameters. The aim of this study is to measure the sero-prevalence of antibodies to SARS-CoV-2 in a community sample drawn from Aden, and more specifically to measure the sero-prevalence of antibodies to SARS-CoV-2 in the general population by sex and age group, in order to ascertain the cumulative population immunity and to estimate the fraction of asymptomatic infection.

The methodology was developed according to the World Health Organization protocol for population-level SARS-CoV-2 antibody testing. It is a one-time crosssectional investigation. It is a community-based study conducted during November to December 2020. Sample size was calculated to be 2000 participants from all age groups. A multi-stage sampling method used. The setting of this study is Aden governorate at southern Yemen (with a population of 997,308) and specifically four districts out of eight districts were randomly selected (two from high incidence districts and two from low incidence districts), within each district two locations (Zones) were selected by simple random methods. And from each location one direction at the central point was randomly selected and all the houses in this direction were selected. In each house, one male and female were selected randomly from all household members to be in the sample.

Data collected by using a well-structured questionnaire; which covers demographic, clinical variables. The questionnaire was digitized using KOBO toolbox application with data validation rules, skip logic and quality control measures integrated to minimize data entry errors. The forms were then deployed through mobile phones.

This allowed for efficient data collection with real-time data transmission directly from the field. The electronic questionnaire for each household was assigned a unique ID that was later used to match respondent field records of the rapid diagnostic (RDT) results and confirmatory enzyme-linked immunosorbent assay (ELISA) testing that was done by the lab teams in the lab. Lab results just like the field records were transmitted electronically results using kobo toolbox to facilitate the analysis process.

A serum sample was collected from each participant; and screened in the field for the presence of COVID-19 virus specific antibodies using RDT by trained laboratory students. For each biological sample collected, the time of collection, the conditions for transportation and the time of arrival at the central public health laboratory (CPHL) in Aden was recorded. Specimens are reach the laboratory within two to three hours after collection. Serum was separated from whole blood and shipped at 4°C or frozen to -20°C or lower (at -80°C) and shipped on dry ice. If the specimens are not likely to reach the laboratory within 72 hours, specimens are frozen, preferably at -80°C, and shipped on dry ice.

The RDT used is Healgen COVID-19 IgG/IgM Cassette. Serum specimen collected for confirmatory testing with a highly specific and sensitive ELISA (WANTAI SARS-CoV-2

Ab ELISA). All the positive RDT were underwent ELISA test and 14% of the negative RDTs underwent ELISA test.

Data were entered in Excel then imported into Epidata and SPSS (version 23) and

STATA 16 for descriptive and inferential statistical analysis. Confidence interval (CI) and Odds ratio (OR) were used to test the difference in prevalence rate, t-test and chi-square test were used when it is appropriates. Multivariate analysis was used to assess the impact of social and risk factors of COVID-19 infection. A significance level of 0·05 was used. 

The research team visited 1138 houses, one or two individuals from each household (HH) except in 218 households (19%) were three or four individuals included HH. The total questionnaires returned from the field survey were 2006, but five of the questionnaires were duplicated in data entry for the same person, so five questionnaires are excluded from the analysis, and data of 2001 people were truly involved in this analysis. The study included all age groups and both males and females from four districts out of eight districts of Aden. The mean age of participants is 33·8 years (±17.1), the median age is 31 years (IQR = 25), the range of the age from one month to 90 years. Figures 1a presented the population pyramid of the studied group (from four districts of Aden). Number of children in groups (<5, and 5-15 years) in the study group were not met with same groups in the population of Aden. Inclusion of children in research is of high ethical concern that limit obtaining representative number from this group.

Detection of SARS-CoV-2 antibodies were performed in the field by RDT giving 610

RDTs positive, all RDT positive and 14% of RDT negative samples were validated by ELISA test in the CPHL of Aden, the confirmation test shows that 549 samples were confirmed by ELISA as true positive. Table 1 shows the prevalence of COVID-19 by districts and compare it with prevalence by RDT. The prevalence of SARS-CoV-2 antibodies based on RDT and qualified by ELISA is 27·4% (CI95% 25·6% -29·3%).

Distribution of the final sample selected for analysis (549 persons) by age and sex is presented in figure 1b .

Prevalence of the different antibodies by using RDT and confirmed by ELISA is presented in table 2, Prevalence of IgG is 25% (CI95% 23·2% -26·9%) while prevalence of IgM is very low 0·2% (CI95% 0·1% -0·4%)

The prevalence of asymptomatic COVID-19 infection among all the study group in Aden was 7·8% (157/2001). The proportion of symptomatic infection among RDT positive persons in this survey was 71·4% (reported at least one symptom related to , while only 28·6% of the COVID-19 infected persons were asymptomatic. Table 3 .

The prevalence of SARS-CoV-2 antibodies is 27·5% (CI95% 25·6% -29·3% patient are significant factors to COVID-19 infection. Table 5 Discussion Serological evidence of SARS-COV-2 antibodies can be a better estimation of the actual number of infected patients. Seroprevalence is measures as the number of people among the study population had antibodies against certain agent (here is the SARS-CoV-2 virus) at one time, as measured by serology tests. Therefore, serological recognition of specific antibodies against SARS-CoV-2 can better estimate the accurate number of infections (Zaidi S et al, 2021) .

shown disparity. The rate is low in developed world ranging from 5% in Spain (Pollán M et al, 2020) and 6·9% in the USA (Havers FP et al, 2020) . In a recent systematic review; SARS-CoV-2 seroprevalence in the general population varied from 0·37% to 22·1%, with a pooled estimate of 3·38% (95%CI 3·05-3·72%; 15,879/399,265) and on a regional level, seroprevalence varied from 1·45% (CI95% 0·95-1·94%), in South America to 5.27% (3.97-6.57%) in Northern Europe (Rostami A et al, 2020) .

In the first seroprevalence study in Yemen, we found that SARS-CoV-2 antibodies were present among 27·4% of the study population in Aden. Although our results are in contrast with western population findings, it is consistent with the population studies in developing countries; i.e., 22% for Iran and 22-33% for India (Rostami A et al, 2020 . Shakiba M et al, 2020 & Bhattacharyya R et al, 2020 and 34% for Pakistan (Zaidi S et al, 2021) ; this high prevalence may be explained by lacking of public health measures in Aden.

Prevalence of specific antibodies in this study revealed that prevalence of IgG is 25% which is more than what was reported in Brazil (8·3%) (Borges et al, 2020) . The same finding is reporting in Italy (4·5%) (Alessi D et al, 2020) .

The methodological difference is explained the high prevalence of COVID19 antibodies in Aden, as most of the published studies targeted either specific groups or specific locations like asymptomatic individuals available in markets in Brazil study. In this study; house to house survey is the method used that targeted a broad group of people and the research team has no background about the infection or the disease history. In situation like Yemen, it is difficult to eliminate selection bias in real field, so this may overestimate the seroprevalence. The major disadvantage is that resulting estimates will often not reflect the true seroprevalence in the underlying population due to selection bias (Shook-Sa BE et al, 2020) . Prevalence of asymptomatic COVID-19 infection in this study (8·5%) are consistent with the prevalence reported in the studies mentioned above.

The level of SARS-CoV-2 antibodies in the study population may not reflect the level of herd immunity. This conclusion may be because no vaccine available at the time of this survey and the level of susceptibility is still high. The point at which the proportion of susceptible individuals falls below the threshold needed for transmission is known as the herd immunity threshold (Anderson R & May R, 1985) .

Above the immunity threshold; the remaining susceptible people may indirectly benefit from infection. Zaidi S et al (2020) concluded in their study in Pakistan that seroprevalence SARS-CoV-2 antibodies is 36%, and it is still a bit far from herd immunity that needs to be at least 60-70% in general population. Moreover, we don't know if previous infection of SARS-CoV-2 in Aden provides protection against the new variants that are transmissible and virulent.

The prevalence of SARS-CoV-2 antibodies in this study is high in all age groups and being increase from childhood to adolescents and adults. The same conclusions were reported in the USA; SARS-CoV-2 seroprevalence to be lower in older adults compared with younger adults across nearly all jurisdictions (Anand S et al, 2020 & Stringhini S et al, 2020 . With endemic corona viruses, seroprevalence typically increases through childhood into early adulthood ) and a few studies of SARS-CoV-2 have shown seroprevalence to be lower in children and adolescents younger than 18 years compared with young adults (Pollán M et al, 2020) .

Regarding sex, in this study sero-prevalence of SARS-CoV-2 antibodies is higher in females than males, it could suggest greater risk of household transmission. Bajema KL et al (2021) in their sero-prevalence study in the USA reported that there were no consistent differences between men and women. In contrast; in certain states, seroprevalence was higher in women while in others seroprevalence was often higher in men. A high Household transmission in this study was observed as high prevalence was reported in housewives and participants with SARS-CoV-2 antibodies had contacts a COVID-19 patients. SARS-CoV-2 is more transmissible in households (jing QL et al, 2020) ; household contacts and those travelling with a case were at higher risk of infection (Bi Q et al, 2020) . Cheng HY et al (2020) concluded in their study in Taiwan that the attack rate was higher among family contacts.

In this study about 72% of participants with RDT positive for COVID-19 had at least one symptom related to COVID-19. In a systematic review conducted by Buitrago-Garcia D et al (2020) they found that in 79 studies in a range of different settings, 20% (CI95% 17%-25%), of people with SARS-CoV-2 infection remained asymptomatic during follow-up, and in seven studies of defined populations screened for SARS-CoV-2 and then followed, 31% (CI95% 26%-37%) remained asymptomatic. This result is consistent with the results of the current study in Aden.

While all the RDT positive samples were re-tested by ELISA, only 14% of RDT negative were re-tested by ELISA test where 549 RDT positive were positive by ELISA. Subjects had RDT positive and ELISA negative were excluded from the analysis. Also; subjects with ELISA positive and RDT negative were excluded from the analysis, so this method may underestimate the true prevalence. Another limitation is that the measurements are only in a small random population in Aden.

In the future studies it is important to test all the participants by ELISA test and increase the sample size.

Even though high prevalence of SARS-CoV-2 antibodies was reported, it does not suggest herd immunity, as more than 70% of all participants is still susceptible. As

Yemen anticipates another wave of COVID-19, enhancing population immunity is recommended by introducing COVID-19 vaccine. Females, housewives and history of contacts are among the highest infected group with COVID-19 infection in the studied sample. Also, health and education setting are sites of possible exposure due to lack of distancing.

Bin-Ghouth AS: principal investigator, manage all stages of the research from proposal conceptualization to study design and preparing the questionnaire, training data collectors, field-work supervision, formal analysis including maintain research data (software code) for interpreting the data and for initial use and later re-use.

Author work actively in writing the first and the final draft. Al-Shoteri SH: preparing the lab methodology, train lab students who collect blood specimens from the field.

A-Shoterri supervise the field-work and the lab validation process, contribute in reviewing the data analysis, and work actively in reviewing the final report. training of data collectors, supervise the field-work and reviewing the final report.

Thabet N: training of data collectors, supervise the field-work and secure all the field and lab logistics. Murshed A, Omara S: training of data collectors, supervise the fieldwork, design the digital questionnaire. They follow the dashboards, finalize the formal analysis including maintain the software for field-work and lab work.

Data sharing the research data set can be accessed by researchers and subject to authors' agreement including de-identified participant data, analysis format and the questionnaire and informed consent after the article is published. Email address of the corresponding author is the way to share data with others. Primary data set can be applied for further training in statistical analysis, epidemiological training upon agreement of authors. 

La prevalenza della risposta immunitaria a SARS-CoV-2 nella popolazione di Borgosesia (VC): una strategia di sorveglianza in fase postlockdown?

Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study

Vaccination and herd immunity to infectious diseases

Estimated SARS-CoV-2 Seroprevalence in the US as of

Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: a case study in Delhi, India

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis

Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset

The need for COVID-19 research in low-and middle-income countries

Seroprevalence of antibodies to SARS-CoV-2 in 11 sites in the United States

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Looming threat of COVID-19 infection in Africa: act collectively, and fast

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Estimation Without Representation: Early Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Studies and the Path Forward

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

WHO a. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection. May, 2020. WHO b. WHO coronavirus diseases (COVID-19) dashboard. Available at: www.covid19.who.int/table (extracted from Dr Abeer Shaif presentation in the training session of seroprevalence surveyors

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19

Authors are pleasures to thank WHO/ EMR office and Yemen